Both agonists tended to induced slightly greater releases of PDGF (Fig 2A) and PF4 (C) in T2DM patients than in control subjects (P values ranging from 0.09 to 0.24), whilst they induced similar releases of VEGF (B) and TSP-1 in patients and controls. Here, VEGFA is linked to type 2 diabetes mellitus.